Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL.

Oncoimmunology. 2016 Dec 23;6(1):e1261779. doi: 10.1080/2162402X.2016.1261779. eCollection 2017.

2.

Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk.

Li J, Shayan G, Avery L, Jie HB, Gildener-Leapman N, Schmitt N, Lu BF, Kane LP, Ferris RL.

Oncoimmunology. 2016 Sep 22;5(10):e1200778. eCollection 2016.

3.

Novel Effector Phenotype of Tim-3+ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients.

Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL.

Clin Cancer Res. 2018 Sep 15;24(18):4529-4538. doi: 10.1158/1078-0432.CCR-17-1350. Epub 2018 Apr 30.

4.

Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM.

Neuro Oncol. 2017 Jun 1;19(6):796-807. doi: 10.1093/neuonc/now287.

5.

Increased PD-1+ and TIM-3+ TILs during Cetuximab Therapy Inversely Correlate with Response in Head and Neck Cancer Patients.

Jie HB, Srivastava RM, Argiris A, Bauman JE, Kane LP, Ferris RL.

Cancer Immunol Res. 2017 May;5(5):408-416. doi: 10.1158/2326-6066.CIR-16-0333. Epub 2017 Apr 13.

6.

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.

Kim JE, Patel MA, Mangraviti A, Kim ES, Theodros D, Velarde E, Liu A, Sankey EW, Tam A, Xu H, Mathios D, Jackson CM, Harris-Bookman S, Garzon-Muvdi T, Sheu M, Martin AM, Tyler BM, Tran PT, Ye X, Olivi A, Taube JM, Burger PC, Drake CG, Brem H, Pardoll DM, Lim M.

Clin Cancer Res. 2017 Jan 1;23(1):124-136. doi: 10.1158/1078-0432.CCR-15-1535. Epub 2016 Jun 29.

7.

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL.

Cancer Res. 2017 Nov 15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. Epub 2017 Sep 13.

8.

Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.

Oweida A, Hararah MK, Phan A, Binder D, Bhatia S, Lennon S, Bukkapatnam S, Van Court B, Uyanga N, Darragh L, Kim HM, Raben D, Tan AC, Heasley L, Clambey E, Nemenoff R, Karam SD.

Clin Cancer Res. 2018 Nov 1;24(21):5368-5380. doi: 10.1158/1078-0432.CCR-18-1038. Epub 2018 Jul 24.

PMID:
30042205
9.

Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines.

Liu J, Zhang S, Hu Y, Yang Z, Li J, Liu X, Deng L, Wang Y, Zhang X, Jiang T, Lu X.

J Immunother. 2016 May;39(4):171-80. doi: 10.1097/CJI.0000000000000122.

PMID:
27070448
10.

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.

Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC.

J Exp Med. 2010 Sep 27;207(10):2187-94. doi: 10.1084/jem.20100643. Epub 2010 Sep 6. Erratum in: J Exp Med. 2011 Jun 6;208(6):1331.

11.

PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.

Zelba H, Bedke J, Hennenlotter J, Mostböck S, Zettl M, Zichner T, Chandran A, Stenzl A, Rammensee HG, Gouttefangeas C.

Cancer Immunol Res. 2019 Sep 4. doi: 10.1158/2326-6066.CIR-19-0146. [Epub ahead of print]

PMID:
31484656
12.

Immune-Checkpoint Blockade Opposes CD8+ T-cell Suppression in Human and Murine Cancer.

Pfannenstiel LW, Diaz-Montero CM, Tian YF, Scharpf J, Ko JS, Gastman BR.

Cancer Immunol Res. 2019 Mar;7(3):510-525. doi: 10.1158/2326-6066.CIR-18-0054. Epub 2019 Feb 6.

PMID:
30728151
13.

Immune checkpoint proteins PD-1 and TIM-3 are both highly expressed in liver tissues and correlate with their gene polymorphisms in patients with HBV-related hepatocellular carcinoma.

Li Z, Li N, Li F, Zhou Z, Sang J, Chen Y, Han Q, Lv Y, Liu Z.

Medicine (Baltimore). 2016 Dec;95(52):e5749. doi: 10.1097/MD.0000000000005749.

14.

PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.

Webb JR, Milne K, Nelson BH.

Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8.

15.

Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.

Cai C, Xu YF, Wu ZJ, Dong Q, Li MY, Olson JC, Rabinowitz YM, Wang LH, Sun Y.

World J Urol. 2016 Apr;34(4):561-7. doi: 10.1007/s00345-015-1656-7. Epub 2015 Aug 8.

PMID:
26253654
16.

Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer.

Guo Z, Cheng D, Xia Z, Luan M, Wu L, Wang G, Zhang S.

J Transl Med. 2013 Sep 17;11:215. doi: 10.1186/1479-5876-11-215.

17.

Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.

Hladíková K, Partlová S, Koucký V, Bouček J, Fonteneau JF, Zábrodský M, Tachezy R, Grega M, Špíšek R, Fialová A.

Oral Oncol. 2018 Jul;82:75-82. doi: 10.1016/j.oraloncology.2018.05.010. Epub 2018 May 26.

PMID:
29909905
18.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.

Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.

19.

TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas.

Li Z, Liu X, Guo R, Wang P.

Tumour Biol. 2017 May;39(5):1010428317698352. doi: 10.1177/1010428317698352.

PMID:
28475007
20.

[Expression and distribution of programmed death receptor 1 and T cell immunoglobulin mucin 3 in breast cancer microenvironment and its relationship with clinicopathological features].

Shen H, Sheng H, Lu JJ, Feng C, Yao M, Pan H, Xu LS, Shen JF, Zheng Y, Zhou YL.

Zhonghua Yi Xue Za Zhi. 2018 May 8;98(17):1352-1357. doi: 10.3760/cma.j.issn.0376-2491.2018.17.014. Chinese.

PMID:
29764038

Supplemental Content

Support Center